Potential biomarker for screening nasopharyngeal carcinoma: three-microRNA panel in serum.

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-06-30 Epub Date: 2025-06-26 DOI:10.21037/tcr-2024-2213
Xutai Li, Zhenjian Ge, Wenkang Chen, Yingqi Li, Shengjie Lin, Yutong Wu, Pengwu Zhang, Huimei Zhou, Yongqing Lai
{"title":"Potential biomarker for screening nasopharyngeal carcinoma: three-microRNA panel in serum.","authors":"Xutai Li, Zhenjian Ge, Wenkang Chen, Yingqi Li, Shengjie Lin, Yutong Wu, Pengwu Zhang, Huimei Zhou, Yongqing Lai","doi":"10.21037/tcr-2024-2213","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is a prevalent form of cancer in Southeast Asia, characterized by distinctive epidemiological attributes, and its occurrence is influenced by factors such as race, age, and gender. Prior research has highlighted the potential of serum microRNA (miRNA) profiling as a non-invasive biomarker for cancer detection. The objective of this study was to ascertain the miRNAs that are specifically linked to the diagnosis of NPC.</p><p><strong>Methods: </strong>A three-phase study was conducted, involving a total of 112 participants (56 NPC patients and 56 healthy controls). Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was employed to measure the expression levels of miRNAs in NPCs and healthy controls (HCs). The diagnostic capability of serum miRNAs for NPCs was assessed using receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC). Furthermore, a diagnostic panel consisting of three miRNAs with high efficiency was constructed using inverse stepwise logistic regression. In addition, we investigated the biological functions of candidate miRNAs.</p><p><strong>Results: </strong>When compared to healthy controls, the blood of NPC patients had significantly dysregulated levels of five miRNAs (hsa-miR-363-3p, hsa-miR-106a-5p, hsa-miR-20b-5p, hsa-miR-200a-3p, hsa-miR-200b-3p). In order to create the diagnostic panels, hsa-miR-20b-5p, hsa-miR-200b-3p and hsa-miR-106a-5p were used. The panel's AUC was 0.925 [95% confidence interval (CI): 0.858-0.967; P<0.001; sensitivity: 94.64%; specificity: 76.92%]. According to the Gene Expression Profiling Interactive Analysis (GEPIA) database results, the target genes <i>AFAP1L1</i>, <i>GPT2</i>, <i>PPP1R12B</i>, <i>PRNP</i> and <i>SGIP1</i> in the three-miRNA panel were good candidates.</p><p><strong>Conclusions: </strong>Our three-miRNA panel (hsa-miR-20b-5p, hsa-miR-200b-3p and hsa-miR-106a-5p) is anticipated to be a promising non-invasive biomarker for NPC screening and diagnosis.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 6","pages":"3554-3564"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268783/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2024-2213","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Nasopharyngeal carcinoma (NPC) is a prevalent form of cancer in Southeast Asia, characterized by distinctive epidemiological attributes, and its occurrence is influenced by factors such as race, age, and gender. Prior research has highlighted the potential of serum microRNA (miRNA) profiling as a non-invasive biomarker for cancer detection. The objective of this study was to ascertain the miRNAs that are specifically linked to the diagnosis of NPC.

Methods: A three-phase study was conducted, involving a total of 112 participants (56 NPC patients and 56 healthy controls). Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was employed to measure the expression levels of miRNAs in NPCs and healthy controls (HCs). The diagnostic capability of serum miRNAs for NPCs was assessed using receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC). Furthermore, a diagnostic panel consisting of three miRNAs with high efficiency was constructed using inverse stepwise logistic regression. In addition, we investigated the biological functions of candidate miRNAs.

Results: When compared to healthy controls, the blood of NPC patients had significantly dysregulated levels of five miRNAs (hsa-miR-363-3p, hsa-miR-106a-5p, hsa-miR-20b-5p, hsa-miR-200a-3p, hsa-miR-200b-3p). In order to create the diagnostic panels, hsa-miR-20b-5p, hsa-miR-200b-3p and hsa-miR-106a-5p were used. The panel's AUC was 0.925 [95% confidence interval (CI): 0.858-0.967; P<0.001; sensitivity: 94.64%; specificity: 76.92%]. According to the Gene Expression Profiling Interactive Analysis (GEPIA) database results, the target genes AFAP1L1, GPT2, PPP1R12B, PRNP and SGIP1 in the three-miRNA panel were good candidates.

Conclusions: Our three-miRNA panel (hsa-miR-20b-5p, hsa-miR-200b-3p and hsa-miR-106a-5p) is anticipated to be a promising non-invasive biomarker for NPC screening and diagnosis.

筛查鼻咽癌的潜在生物标志物:血清中3 - microrna面板。
背景:鼻咽癌(鼻咽癌)是东南亚地区常见的一种癌症,具有独特的流行病学特征,其发生受种族、年龄、性别等因素的影响。先前的研究已经强调了血清microRNA (miRNA)谱分析作为癌症检测的非侵入性生物标志物的潜力。本研究的目的是确定与鼻咽癌诊断特异性相关的mirna。方法:采用三期研究方法,共纳入112名受试者(NPC患者56例,健康对照56例)。采用逆转录定量聚合酶链反应(RT-qPCR)检测NPCs和健康对照(hc)中miRNAs的表达水平。采用受试者工作特征(ROC)曲线和ROC曲线下面积(AUC)评估血清mirna对npc的诊断能力。此外,利用逆逐步逻辑回归构建了一个由三个mirna组成的高效率诊断面板。此外,我们还研究了候选mirna的生物学功能。结果:与健康对照组相比,鼻咽癌患者血液中5种mirna (hsa-miR-363-3p、hsa-miR-106a-5p、hsa-miR-20b-5p、hsa-miR-200a-3p、hsa-miR-200b-3p)水平显著失调。为了制作诊断面板,使用了hsa-miR-20b-5p、hsa-miR-200b-3p和hsa-miR-106a-5p。panel的AUC为0.925[95%置信区间(CI): 0.858-0.967;三mirna面板中的PAFAP1L1、GPT2、PPP1R12B、PRNP和SGIP1是较好的候选。结论:我们的三种mirna (hsa-miR-20b-5p, hsa-miR-200b-3p和hsa-miR-106a-5p)有望成为鼻咽癌筛查和诊断的一种有前途的非侵入性生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信